ReviewSchmerz (Berlin, Germany)2025
[Diabetes mellitus-a risk factor for pain].
Review in Schmerz (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07316322 (Comparison of Central Sensitization in Painful and Painless Diabetic Peripheral Neuropathy Phenotypes), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of Central Sensitization in Painful and Painless Diabetic Peripheral Neuropathy Phenotypes: A Multidimensional Psychophysiological Assessment
Who cites it
1 citing paper in PubMed.
- Beyond Neuropathy: The Mechanisms and Phenotypes of Diabetes-Related Musculoskeletal Pain.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A high percentage of the world's population suffers from diabetes mellitus (DM). The disease leads to considerable DM-related pathological consequences and aggravates disease processes and pain as a comorbidity. This has a significant impact on the quality of life of these patients. This article describes DM-induced mechanisms that may contribute to increased pain. Diabetic patients exhibit low-grade systemic inflammation, high levels of blood glucose, and increased formation and accumulation of advanced glycation end products (AGEs). These factors can activate intracellular inflammatory signaling pathways and induce reactive oxygen species (ROS) formation, which can lead to the release of cytokines, oxidative stress, and mitochondrial dysfunction. These processes lead to increased local inflammation and damage to blood vessels and nerve fibers, which are considered to be causes of many diabetic complications. The increased release of pro-inflammatory mediators contributes to peripheral and central sensitization and thus to increased acute and chronic pain in diabetic patients. About 50% of people with DM develop diabetic neuropathy, which can cause numbness, discomfort, or severe pain. In addition, diabetic patients have an increased incidence of musculoskeletal disorders, which can cause additional pain.
Indexed as
Identifiers
40875021What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.